Isoray recently announced that its brachytherapy delivery system has been used in the first prostate cancer surgery.
The company’s Blu Build real-time Cesium-131 brachytherapy delivery system was used at the Hollings Cancer Center at the Medical University of South Carolina.
“Here at Hollings Cancer Center, we are proud to continue our legacy as innovators dedicated to bringing the very best in medical advancements and care to our patients,” Dr. David Marshall, a radiation oncology professor and medical director of the clinical trials office at the Hollings Cancer Center, said in a press release.
Isoray’s device is a disposable, single-use device that has added maneuverability. It allows doctors to deliver a high radiation dose to targeted prostate cancer and can limit the impact on areas around the cancer compared to other treatment options.
“No two patients are exactly alike. What Blu Build provides physicians is a real-time means to individually customize and deliver a precise placement of Cesium-131 brachytherapy seeds tailored to the patient’s anatomy and cancer as the physician is seeing it in the operating room at the time of surgery,” Marshall said.
Isoray is currently the only company that produces Cesium-131 brachytherapy, which also expands internal radiation treatment for prostate, brain, gynecological, lung, head and neck, esophageal and abdominal wall cancers.
“Blu Build provides each patient personalized treatment for their specific situation with the unique treatment benefits of Cesium-131 brachytherapy,” said Lori Woods, CEO of Isoray. “This is an important step forward in prostate cancer treatment.”